Recombinant DENV-2 Envelope Protein E: Structure, Activity, and Applications
The Dengue virus (DENV) is a mosquito-borne flavivirus that infects over 390 million people worldwide each year. It is the leading cause of mosquito-borne viral illness in humans, with symptoms ranging from mild flu-like illness to severe hemorrhagic fever and shock. There are four distinct serotypes of DENV, and infection with one serotype does not provide immunity against the others. This makes the development of a safe and effective vaccine a major public health priority.
The DENV-2 Envelope protein E is a key component of the viral envelope and plays a critical role in the virus’s entry into host cells. It is a highly immunogenic protein and is the main target for neutralizing antibodies. Recombinant DENV-2 Envelope protein E is produced through genetic engineering techniques, making it a valuable tool for research and vaccine development.
Structure of Recombinant DENV-2 Envelope Protein E
The DENV-2 Envelope protein E is a glycoprotein with a molecular weight of approximately 50 kDa. It is composed of three distinct domains: domain I, II, and III. Domain I is the central domain and contains the fusion peptide, which is responsible for the fusion of the virus with host cell membranes. Domain II is the dimerization domain, and domain III is the immunoglobulin-like domain that contains the receptor-binding site. The structure of Recombinant DENV-2 Envelope protein E is similar to that of the native protein, making it an ideal antigen for vaccine development.
Activity of Recombinant DENV-2 Envelope Protein E
The primary function of the DENV-2 Envelope protein E is to mediate viral entry into host cells. It does this by binding to cellular receptors and triggering conformational changes that allow the virus to fuse with the cell membrane. Recombinant DENV-2 Envelope protein E is also highly immunogenic, and its activity as an antigen makes it a valuable tool for diagnostic tests and vaccine development. It can elicit a strong antibody response, which is crucial for neutralizing the virus and providing protection against infection.
Applications of Recombinant DENV-2 Envelope Protein E
Vaccine Development
The development of a safe and effective vaccine against DENV is a major public health priority. Recombinant DENV-2 Envelope protein E is a key component of many candidate vaccines, either as a standalone antigen or in combination with other viral proteins. Its ability to elicit a strong immune response and its structural similarity to the native protein make it an ideal candidate for vaccine development.
Diagnostic Tests
Recombinant DENV-2 Envelope protein E is also used in diagnostic tests to detect the presence of DENV antibodies in patient samples. These tests are crucial for accurate diagnosis and surveillance of DENV infections. The highly immunogenic nature of the protein makes it an excellent antigen for these tests, ensuring reliable and sensitive detection of DENV antibodies.
Research Tool
Recombinant DENV-2 Envelope protein E is a valuable research tool for studying the structure and function of the DENV virus. Its production through genetic engineering techniques allows for large-scale production and purification, making it more accessible for research purposes. It is also used in studies to understand the immune response to DENV infection and aid in the development of new therapeutic strategies.
Conclusion
Recombinant DENV-2 Envelope protein E is a key component of the Dengue virus and plays a crucial role in viral entry and immune response. Its structural similarity to the native protein and ability to elicit a strong immune response make it a valuable tool for vaccine development, diagnostic tests, and research. With the increasing global burden of DENV infections,
There are no reviews yet.